MapLight Q2 Loss Widens to $60.2M; $150M Private Placement Extends Runway to 2028
MPLT sits 29% above its 52-week low of $9.1.
Summary
MapLight's Q2 loss widened to $60.2 million, but a $150 million private placement announced today is expected to fund operations through 2028.
Key Events · Earnings and Guidance · MPLT
-
Q2 Net Loss Widens
Net loss for Q2 2026 was $60.2 million, up from $29.8 million in Q2 2025, driven by a $26.6 million increase in R&D expenses to $53.4 million.
-
Cash Runway Extended
Cash, cash equivalents, and investments totaled $351.3 million as of June 30, 2026. Combined with the $150 million private placement, the company expects to fund operations through 2028.
-
Private Placement Terms
The company agreed to sell 9,197,887 shares at $11.38 per share and pre-funded warrants for 3,983,168 shares, with gross proceeds of approximately $150 million.
-
CFO Transition
CFO Vishwas Setia departed on June 18, 2026, and Jonathan Gillis was appointed interim CFO, as previously disclosed in an 8-K.
Analysis · MPLT · Life Sciences
MapLight reported a Q2 net loss of $60.2 million, bringing the six-month loss to $120.9 million, driven by a doubling of R&D expenses as the company advances its clinical programs. The company ended the quarter with $351.3 million in cash and investments, and the newly announced $150 million private placement is expected to extend its cash runway through 2028. The filing also confirms the departure of CFO Vishwas Setia and the appointment of Jonathan Gillis as interim CFO, adding to recent management turnover.
At the time of this filing, MPLT was trading at $11.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $493.5M. The 52-week trading range was $9.10 to $40.43. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.